By Jaime Llinares Taboada

 

CureVac NV said Tuesday that it has filed a patent infringement lawsuit in a German court against BioNTech SE.

The Nasdaq-listed biopharmaceutical company said the lawsuit seeks fair compensation for infringement of a portfolio of CureVac's intellectual property rights which are used in BioNTech and Pfizer Ltd.'s mRNA COVID-19 vaccine.

CureVac said its IP portfolio protects inventions essential to the design and development of BioNTech's vaccine.

"Accordingly, CureVac's intellectual property rights need to be acknowledged and respected in the form of a fair compensation to reinvest into the further advancement of mRNA technology and the ongoing development of new classes of life saving medicines," the company said.

 

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

 

(END) Dow Jones Newswires

July 05, 2022 07:46 ET (11:46 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more CureVac NV Charts.
CureVac NV (NASDAQ:CVAC)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more CureVac NV Charts.